Mounjaro vs. New Obesity Drugs: Why Wave-007 Is Stealing the Spotlight
Mounjaro vs. New Obesity Drugs: Why Wave-007 Is Stealing the Spotlight  
Podcast: On The Pen GLP-1 News
Published On: Tue Dec 09 2025
Description: Send a textEpisode Timeline & Main Topics00:00 — Opening & Community Update• First week doing the podcast fully live thanks to the On The Pen community• Overview of why this week’s news is a major turning point in obesity medicine02:30 — Introducing the “One-and-Done” Obesity Drug (Wave Life Sciences)• WVE-007 early data drops• Why this therapy is unlike GLP-1s or any nutrient-stimulated hormone• Fat loss results and lean-mass increase06:30 — How Wave-007 Works: INHBE Gene Silencing• Mechanism behind visceral fat reduction• Why this shifts the field toward “quality of weight loss”09:15 — Why Lean-Mass Preservation Matters• Current GLP-1 medications and muscle loss• Why women dominate trial enrollment and the larger implications• Medicare patients and the coming wave of GLP-1 coverage13:45 — The Future of Maintenance Therapies• Fractyl Health Revita results• Lilly’s orforglipron maintenance design• Why “holding the line” after GLP-1 therapy is the next major category17:30 — Amylin Agonists: Cagrelintide vs. Eloralintide• Novo’s delays and the strategy behind them• Lilly’s surprising phase 2 results (up to 20% weight loss)• Combination therapies with tirzepatide or retatrutide22:30 — FDA Pipeline Acceleration• Potential removal of traditional phase 3 trials• How this speeds up the arrival of next-generation therapies24:15 — Oral GLP-1 Small Molecules (Structure Therapeutics)• Alaniglipron data and the stock surge• Comparisons to orforglipron and past failures like denuglipron• Why Dave remains skeptical28:40 — Sponsor Break: Shed & Shapa• Access, coaching, and patient support• Using a numberless scale to build a healthier relationship with weight tracking31:10 — Counterfeit Ozempic Warning• New fake lot discovered in U.S. pharmacies• How to identify counterfeit pens• Why this should be a national headline• The broader question of drug supply-chain vulnerability36:00 — Closing Thoughts on the Future of Obesity Medicine• Moving from “more weight loss” to “better weight loss”• Why the field is closer than ever to reshaping obesity as a disease• Gratitude for the community making full-time coverage possible🤝 Visit Our Sponsors!OTPLinks.com Decoding GLP-1 BookDecoding GLP-1: A Guide for Friends and Family of Those On The PenBuy Here: https://amzn.to/3Dc66d4MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:Venmo: OnThePenCa$h App: ManOnMounjaroBECOME A MEMBER:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join👉 My Amazon Affiliate Store:https://www.amazon.com/shop/manonthemounjaroonthepenWATCH MORE!📺 We're Live M/W/F at 11 central: onthepen.tv 📲 Contact Me: dave@onthepen.comThank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.